JavaScript is disabled for your browser. Some features of this site may not work without it.
Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.
Статистика
Жалпы қатысу саны
| Көру | |
|---|---|
| PCN99 Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan | 122 |
Бір айдағы саны
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| PCN99 Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan | 3 | 2 | 5 | 5 | 0 | 2 | 4 |
елдер бойынша
| Көру | |
|---|---|
| United States | 51 |
| Germany | 17 |
| Russia | 16 |
| Sweden | 8 |
| China | 5 |
| Iran | 3 |
| Vietnam | 3 |
| Belgium | 1 |
| France | 1 |
| Kazakhstan | 1 |
қалалар бойынша
| Көру | |
|---|---|
| Louisville | 17 |
| Oakland | 12 |
| Moscow | 8 |
| Boardman | 7 |
| Shanghai | 5 |
| Hanoi | 3 |
| Des Moines | 2 |
| Menlo Park | 2 |
| Anaheim | 1 |
| Andover | 1 |
Ұсыну нұсқаулығы